Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Cantor Fitzgerald
Express Scripts
UBS
Johnson and Johnson
Moodys

Generated: August 18, 2019

DrugPatentWatch Database Preview

Claims for Patent: 8,945,005

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,945,005
Title:Controlled activation ingestible identifier
Abstract: Controlled activation identifiers for use in ingestible compositions, such as pharma-informatics enabled compositions, are provided. The identifiers include a controlled activation element that provides for activation of the identifier in response to the presence of a predetermined stimulus at a target site of interest. The invention finds use in a variety of different applications, including but not limited to, monitoring of therapeutic regimen compliance, tracking the history of pharmaceutical agents, etc.
Inventor(s): Hafezi; Hooman (Redwood City, CA), Robertson; Timothy (Belmont, CA), Colliou; Olivier (Los Gatos, CA), Zdeblick; Mark (Portola Valley, CA)
Assignee: Proteus Digital Health, Inc. (Redwood City, CA)
Application Number:12/447,172
Patent Claims: 1. A pharmaceutical composition comprising: a pharmaceutical active agent; a controlled activation identifier that transmits a signal upon contact with a target site of a body, wherein the signal is a conductive signal and wherein the controlled activation identifier comprises first and second electrodes that are configured to create a voltaic cell when in contact with a conducting fluid at the target site, wherein the voltaic cell supplies power to the controlled activation identifier, and wherein the controlled activation identifier is configured to transmit the conductive signal through tissue of to the body upon the first and second electrodes contacting the conducting fluid at the target site and the voltaic cell supplying power to the controlled activation identifier; and a pharmaceutically acceptable carrier.

2. The pharmaceutical composition of claim 1, wherein the first and second electrodes transmit the conductive signal.

3. A controlled activation ingestible identifier that transmits a signal upon contact with a conducting fluid present at a target site of a body, wherein the signal is a conductive signal and wherein the controlled activation identifier comprises first and second electrodes that are configured to create a voltaic cell when in contact with the conducting fluid at the target site, wherein the voltaic cell supplies power to the controlled activation identifier, and wherein the controlled activation identifier is configured to transmit the conductive signal through tissue of the body upon the first and second electrodes contacting the conducting fluid at the target site and the voltaic cell supplying power to the controlled activation identifier.

4. The controlled activation ingestible identifier according to claim 3, wherein the identifier comprises: a solid support; wherein the first and second electrodes comprise first and second materials with dissimilar electrochemical activities and wherein the electrodes are present on a surface of the solid support.

5. The controlled activation ingestible identifier according to claim 4, wherein the identifier further comprises a dried conductive medium precursor.

6. The controlled activation ingestible identifier according to claim 5, wherein the identifier further comprises a protective barrier that retains the dried conductive medium precursor.

7. The controlled activation ingestible identifier according to claim 4, wherein the identifier further comprises a protective barrier.

8. The controlled activation ingestible identifier according to claim 7, wherein the protective barrier is a semipermeable membrane.

9. The controlled activation ingestible identifier according to claim 7 wherein the protective barrier is a solid barrier comprising a flow path.

10. The controlled activation ingestible identifier according to claim 9, wherein the flow path is a capillary flow path.

11. The controlled activation ingestible identifier according to claim 10, wherein the capillary flow path comprises at least one surface that has been surface energy modified to enhance hydrophilic fluid flow through the capillary flow path.

12. The controlled activation ingestible identifier according to claim 4, wherein the identifier is protected by a barrier that disrupts upon contact with a fluid having sufficient conductivity to activate the identifier in a predetermined manner.

13. The controlled activation ingestible identifier according to claim 4, wherein the identifier is protected by a polymeric coating that dissolves upon contact with a fluid in a time-delayed manner.

14. The controlled activation ingestible identifier according to claim 4, wherein the identifier further comprises a signal producing system that transmits a signal when the dried conductive medium precursor is combined with water to produce a conductive medium that conductively couples the first and second materials.

15. The controlled activation ingestible identifier according to claim 3, wherein the first and second electrodes transmit the conductive signal.

16. A system comprising: a controlled activation ingestible identifier that transmits a signal upon contact with a conducting fluid present at a target site of a body, wherein the signal is a conductive signal and wherein the controlled activation identifier comprises first and second electrodes that are configured to create a voltaic cell when in contact with the conducting fluid at the target site, wherein the voltaic cell supplies power to the controlled activation identifier, and wherein the controlled activation identifier is configured to transmit the conductive signal through tissue of the body upon the first and second electrodes contacting the conducting fluid at the target site and the voltaic cell supplying power to the controlled activation identifier; and a receiver for detecting a signal produced by the identifier.

17. The system according to claim 16, wherein the receiver is an in vivo receiver.

18. The system according claim 16, wherein the receiver is an ex vivo receiver.

19. The system according claim 16, wherein the first and second electrodes transmit the conductive signal.

20. A method comprising: administering to a subject a controlled activation ingestible identifier that transmits a signal upon contact with a conducting fluid present at a target site, wherein the controlled activation identifier comprises first and second electrodes that are configured to create a voltaic cell when in contact with the conducting fluid at the target site, wherein the voltaic cell is configured to supply power to the controlled activation identifier, and wherein the controlled activation identifier is configured to transmit the signal through tissue of the body upon the first and second electrodes contacting the conducting fluid at the target site and the voltaic cell supplying power to the controlled activation identifier, wherein the signal is a conductive signal transmitted to a body with first and second electrodes; and transmitting, by the controlled activation identifier, the conductive signal upon contact with the target site of a body.

21. The method of claim 20, wherein the first and second electrodes transmit the conductive signal.

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Healthtrust
Harvard Business School
Baxter
Accenture
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.